Week Ahead In Pharma: FDA Decision, Review Of COVID-19 Vaccine, Data Readouts (Moderna, BCRX, ARVN...) THOUSAND OAKS (dpa-AFX) - The week that just passed by saw a couple of stocks belonging to the healthcare sector record triple-digit gains and nearly a dozen managing to log gains in excess of 50 percent, thanks to positive clinical trial readouts. Greenwich LifeSciences Inc. (GLSI), which closed out the week at $56, delivering over 890%, was the top gainer of the week, following promising five year-data related to its drug candidate GP2 in a phase II clinical trial in HER2 positive women with operable breast cancer. Curis Inc. (CRIS) closed the week at $7.89, recording a weekly gain of nearly 320%, on the back of positive preliminary data from its ongoing phase I study of CA-4948 monotherapy in patients with relapsed or refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes.